RecruitingNot ApplicableNCT05061004
Cephea Early Feasibility Study
Sponsor
Abbott Medical Devices
Enrollment
50 participants
Start Date
Apr 28, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria.
- LVEF ≥ 30%
- In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery.
Exclusion Criteria2
- Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function.
- Need for emergent or urgent surgery.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICECephea Mitral Valve System
Transcatheter mitral valve replacement
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05061004
Related Trials
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
NCT0476112017 locations
Abbott Cephea Mitral Valve Disease Registry
NCT0706967322 locations
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
NCT0468819043 locations
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
NCT052981244 locations
A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.
NCT070865341 location